{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-065386","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.453748+00:00","generated_at":"2026-05-18T09:41:55.298948+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants","bullets":["Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.","Underwriters have 30-day option to purchase up to 576,923 additional shares on same terms.","Proceeds to fund firmonertinib and other pipeline programs, plus working capital.","Expected close July 3, 2025; joint bookrunners: Goldman Sachs, Citigroup, Guggenheim Securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-065386","json":"https://secwatch.observer/filing/0001104659-25-065386.json","markdown":"https://secwatch.observer/filing/0001104659-25-065386.md","text":"https://secwatch.observer/filing/0001104659-25-065386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/0001104659-25-065386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/tm2519401d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:41:55.298948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}